Transcriptome Signature Post Reovirus Treatment In KRAS Mutated Colorectal Cancer. Transcriptome Signature Post Reovirus Treatment In KRAS Mutated Colorectal Cancer

Reovirus propagates with high efficiency in KRAS mutated colorectal cancer (CRC). About 45-50% of CRC patients possess KRAS mutation. Oncolytic reovirus treatment in combination with chemotherapy was tested in patient samples possessing KRAS mutated metastatic CRC. This is the raw data from the peripheral mononuclear cell (PBMC) samples at 4 timepoints (pre treatment, 48 hours, day 8, and day 15). Overall design: Reovirus was administered as a 60-min intravenous infusion for 5 consecutive days every 28 days, at tissue culture infective dose (TCID50) of 3X1010. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood pre and post reovirus administration at 48hr, Day-8, and Day-15. Clariom_D_Human_Assay was used to determine the overall gene expression compared to pre-reovirus treatment by RNA sequencing.